Truist Securities: Eli Lilly's Incretin Portfolio Bolsters Multi-year Growth Potential; Estimates Updated

AI Briefing

• – Eli Lilly's incretin portfolio to drive growth
• – Analysts raise Truist Securities' target price, citing long-term potential
• – Incretin compounds to remain a key growth driver for Eli Lilly